Paediatric Fungal infections

This section summarises published information regarding the concepts in managing invasive fungal infections in children, with specific reference to Aspergillus.

Broadly there are two sections comprising diagnosis and treatment regimes. The data here are sourced and summarised from a series of publications in Clinical Microbiology Infect. 16(9), 1319-53, 2010 by Groll et alWalsh et alDornbusch et al& all these references are more comprehensive than the data compiled here and we recommend referral to the original publications for further detail. 
To view any links to publication please register your name with the site here.

Children and in particular neonates and young infants, are a unique patient population, particularly with respect to fungal infections. 
Invasive fungal infections are dificult to diagnose - but response to treatment and outcome is dependent on a prompt initial diagnosis and the initiation of treatment.

Epidemiology and Clinical Trials

The epidemiology, presentation and pre-disposing conditions show significant differences in paediatric versus adult patients. 
The use of antifungal agents in this patient group requires an understanding of pharmacodynamics and safety issues - which accumulating evidence suggests can not always be empirically derived from data collected on usage in adult groups.

Many antifungal clinical trials have previously excluded paediatric groups so there is a lack of trials of large cohorts- but there is data in the literature for smaller cohorts of paediatric patients- for various antifungal treatments.
New antifungals are continually going into trials - however the need for evaluation in paediatric patients is great.

This website specialises in Aspergillus infections - but the lack of paediatric data has meant that we have included data for other types of fungal infections - where it may be useful. 

Collected articles on pediatric fungal infections (Searchable)

Computed content type (Paediatrics): 


Pediatrics Fungal Infections

Displaying 81 - 90 of 225
Author year
Role of Molecular Biomarkers in the Diagnosis of Invasive Fungal Diseases in Children Huppler AR, Fisher BT, Lehrnbecher T, Walsh TJ, Steinbach WJ 2017
Voriconazole Antifungal Prophylaxis in Children With Malignancies: A Nationwide Study. Pana ZD, Kourti M, Vikelouda K, Vlahou A, Katzilakis N, Papageorgiou M, Doganis D, Petrikkos L, Paisiou A, Koliouskas D, Kattamis A, Stiakaki E, Chatzistilianou M, Vasilatou-Kosmidis H, Polychronopoulou S, Grafakos S, Roilides E. 2018
Efficacy and safety of itraconazole use in infants Chen S, Sun KY, Feng XW, Ran X, Lama J, Ran YP 2016
Toxicity of Vincristine Combined With Posaconazole in Children With Acute Lymphoblastic Leukemia Pekpak E, İleri T, İnce E, Ertem M, Uysal Z 2017
A clinical analysis of micafungin treatment of pulmonary invasive fungal infection in pediatric patients with acute leukemia or post hematopoietic stem cells transplantation Huang K, Qiu KY, Deng LL, Fang JP, Li Y, Guo HX, Zhou DH. 2017
Fungal and Parasitic CNS Infections Singhi P, Saini AG 2017
Antifungal Drugs in Newborns and Children Puia-Dumitrescu M, Smith PB 2017
An investigation of operative outcomes: Pediatric invasive fungal sinusitis Hanba C, Svider PF, Lai W, Raza SN, Sheyn A, Eloy JA, Folbe AJ 2017
A Prospective, International Cohort Study of Invasive Mold Infections in Children Wattier RL1, Dvorak CC1, Hoffman JA2, Brozovich AA3, Bin-Hussain I4, Groll AH5, Castagnola E6, Knapp KM7, Zaoutis TE8, Gustafsson B9, Sung L10, Berman D11, Halasa NB12, Abzug MJ13, Velegraki A14, Sharma TS15, Fisher BT8, Steinbach WJ 2017
Pharmacokinetic Modelling of Voriconazole to Develop an Alternative Dosing Regimen in Children Gastine S, Lehrnbecher T, Müller C, Farowski F, Bader P, Ullmann-Moskovits J, Cornely OA, Groll AH, Hempel G 2017